UPDATE 3-Supernus Pharma's ADHD treatment fails to impress; shares fall
December 06, 2018 at 12:33 PM EST
Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.
